Mode
Text Size
Log in / Sign up
N/A N=70 Double-blind Treatment

Effect of Succinylcholine on Patients Using Statins

Pain

Enrolled (actual)
70
Serious AEs
0.0%
Results posted
Aug 2016
Primary outcome: Primary: Plasma Myoglobin Concentration — 46; 39; 71; 49 ug/l — p=0.018

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Succinylcholine (Drug)
Age
Adult, Older Adult · 40+ yrs
Sex
All
Sponsor
The Cleveland Clinic
Primary completion
Jul 2010

Outcome Measures

OutcomeResultp-value
PRIMARY
Plasma Myoglobin Concentration
46; 39; 71; 49; 77; 47 0.018 sig
SECONDARY
Muscle Pain
34; 26; 2; 0; 1; 4
SECONDARY
Serum Potassium Concentration
4.2; 4.2; 4.0; 3.9
SECONDARY
Change in Plasma Creatine Phosphokinase (CK) Concentration From 2 to 24 Hours Postoperatively
175; 78
SECONDARY
Duration of Succinylcholine Block
4.2; 4.6
SECONDARY
Fasciculation
9; 13; 6; 3; 10; 8

Summary

Based on available mechanistic and clinical information, the investigators propose a nonrandomized study to evaluate the effect of succinylcholine in patients taking statins. The investigators' purpose is to evaluate the effect of succinylcholine on patients taking statins. Patients scheduled to undergo elective surgery (other then orthopedic, spinal, vascular or muscle) with planned endotracheal intubation will be approached regarding participation in the trial. Design of the study is complex because there is no way to randomize patients to statins or no statins and also no way to take them off the statins prior surgery. So statin use will not be randomized; confounding factors will be accounted for by stratification (every 10 years of age from 40-80 and gender) and statistical adjustment. The investigators propose to test the hypothesis that succinylcholine administration increases plasma myoglobin concentration more in patients who are on statins compared to patients who do not.

Eligibility Criteria

Inclusion Criteria

  • Scheduled for elective surgery not involving orthopedic procedure, muscle and spinal surgery
  • ASA Physical Status 1-3

Exclusion Criteria

  • History of liver failure
  • History of renal failure
  • History of neuromuscular disease
  • Increased intraocular pressure
  • Recent major burn
  • Multiple trauma
  • Susceptibility to or family history of malignant hyperthermia
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00986583). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search